Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
TADALAFIL (UNII: 742SXX0ICT) (TADALAFIL - UNII:742SXX0ICT)
Burel Pharmaceuticals, LLC
ORAL
PRESCRIPTION DRUG
Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED). Tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tadalafil tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see Clinical Studies (14.3)]. Administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates [see Clinical Pharmacology (12.2)] . Tadalafil tablets are contraindicated in patients with a known serious hypersensitivity to tadalafil tablets or A
Tadalafil tablets USP are supplied as follows: Tadalafil Tablets USP 2.5 mg are light orange-yellow colored, oval shaped, film-coated tablets debossed with ‘1’ on one side and ‘L’ on the other side. Cartons of 30 (2x15 Unit-dose Tablets) NDC 35573-409-38 Tadalafil Tablets USP 5 mg are light yellow colored, oval shaped, film-coated tablets debossed with ‘56’ on one side and ‘L’ on the other side. Bottles of 30 NDC 35573-410-30 Tadalafil Tablets USP 10 mg are light yellow colored, oval shaped, film-coated tablets debossed with ‘57’ on one side and ‘L’ on the other side. Bottles of 30 NDC 35573-411-30 Tadalafil Tablets USP 20 mg are yellow colored, oval shaped, film-coated tablets debossed with ‘58’ on one side and ‘L’ on the other side. Bottles of 30 NDC 35573-412-30 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep out of reach of children.
Abbreviated New Drug Application
TADALAFIL - TADALAFIL TABLET, FILM COATED BUREL PHARMACEUTICALS, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TADALAFIL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TADALAFIL TABLETS. TADALAFIL TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 INDICATIONS AND USAGE Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) (1.1) the signs and symptoms of benign prostatic hyperplasia (BPH) (1.2) ED and the signs and symptoms of BPH (ED/BPH) (1.3) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks (1.4). DOSAGE AND ADMINISTRATION _Tadalafil tablets for use as needed:_ ED: Starting dose: 10 mg as needed prior to sexual activity. Increase to 20 mg or decrease to 5 mg based upon efficacy/tolerability. Improves erectile function compared to placebo up to 36 hours post dose. Not to be taken more than once per day (2.1). _Tadalafil tablets for once daily use:_ ED: 2.5 mg taken once daily, without regard to timing of sexual activity. May increase to 5 mg based upon efficacy and tolerability (2.2). BPH: 5 mg, taken at approximately the same time every day (2.3) ED and BPH: 5 mg, taken at approximately the same time every day (2.3, 2.4) Tadalafil tablets may be taken without regard to food (2.5). DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg (3). CONTRAINDICATIONS Administration of tadalafil tablets to patients using any form of organic nitrate is contraindicated. Tadalafil tablets were shown to potentiate the hypotensive effect of nitrates (4.1). History of known serious hypersensitivity reaction to tadalafil tablets or ADCIRCA (4.2). Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3). WARNINGS AND PRECAUTIONS Patients should not use tadalafil if sex is inadvisable due to cardiovascular status (5.1). Use of tadalafil with alpha-blockers, antihypertensives or substant Olvassa el a teljes dokumentumot